TIGERMED - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

HANGZHOU TIGERMED CONSULTING CO., LTD.

Hangzhou Tiger Pharmaceutical Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 3347)

Overseas regulatory announcement

This announcement is made by Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (the "Company") pursuant to a Hong Kong joint transaction

made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities of Hong Kong Limited.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. Chairman Ye Xiaoping

Hong Kong, June 5, 2026

As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; The employee director is Mr. Wu Hao; the independent non-executive directors are Mr. Yuan Huagang, Ms. Liu Yuwen and

Mr. Xiao Yaoxi.

Securities code: 300347 Securities abbreviation: Tigermed Announcement No. (2026) 034

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Regarding the repurchase of part of the company's shares, the top ten A-share shareholders and the top ten A-share shareholders without selling restrictions

Announcement on Shareholdings of Shareholders

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that any false records or misleading statements in the announcement

Or bear joint and several liability for major omissions.

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") held its fifth meeting on May 13, 2026.

At the 25th meeting of the Board of Directors, the "Proposal on the Plan to Repurchase the Company's Shares" was reviewed and approved. According to relevant laws

According to regulations, this share repurchase plan still needs to be submitted to the company’s shareholders’ meeting for review. The company has disclosed on May 20, 2026

"About the Convening of the Second Extraordinary Shareholders' Meeting in 2026, the Second A-Share Class Meeting of Shareholders in 2026 and the Second Extraordinary Meeting of Shareholders in 2026

Announcement of H Shareholders Class Meeting". For details, please see the company’s publication on the Juchao Information Network (www.cninfo.com.cn)

related announcements.

According to the "Shenzhen Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 9 - Share Buyback (Revised in 2025)"

and other relevant regulations, the company has disclosed the transaction before the company's board of directors announced the resolution to repurchase shares on May 19, 2026

The names and number of shares held by the top ten shareholders and the top ten A-share shareholders without sales restrictions on the date (i.e. May 13, 2026),

Proportional situation; now the equity registration date for the second extraordinary shareholders’ meeting in 2026 (i.e. June 4, 2026) will be recorded in the register before

The names, number and proportion of shares held by the ten shareholders and the top ten A-share shareholders without selling restrictions are announced as follows:

1. Shareholdings of the top ten A-share shareholders on the equity registration date of the second extraordinary shareholders’ meeting in 2026 (i.e. June 4, 2026)

Situation:

Proportion of total share capital of A shares Serial number Shareholder name Number of shares held (shares) (%) 1 Ye Xiaoping 177,239,541 24.02

2 Cao Xiaochun 51,314,174 6.95

3 Hong Kong Securities Clearing Company Limited 42,369,594 5.74

China Everbright Bank Co., Ltd.- 4 Xingquan business model preferred hybrid securities 36,092,253 4.89 Investment Fund (LOF) Industrial and Commercial Bank of China Co., Ltd.-

5 China-Europe Medical and Health Hybrid Securities Investment 24,089,364 3.26 fund China Merchants Bank Co., Ltd.-Xingquan 6 18,322,959 2.48 Herun Hybrid Securities Investment Fund Industrial Bank Co., Ltd.-Xingquan 7 New Horizons Flexible Configuration Regular Open Mixing 18,227,716 2.47 type-initiated securities investment fund Bank of China Co., Ltd.-Huabao 8 CSI Medical Trading Open Index Certificate 18,071,470 2.45 securities investment funds 9 Shi Xiaoli 9,566,880 1.30

Bank of Shanghai Co., Ltd.-Yinhua 10 CSI Innovative Drug Industry Trading Open 8,242,042 1.12 Index Securities Investment Fund

2. Condition A for the top ten companies on the equity registration date of the second extraordinary shareholders’ meeting in 2026 (i.e. June 4, 2026)

Shareholding status of shareholders:

A-shares are circulated without selling restrictions Serial number Shareholder name Number of shares held (shares) Share capital ratio (%)

1 Ye Xiaoping 44,309,885 7.83

2 Hong Kong Securities Clearing Company Limited 42,369,594 7.48 China Everbright Bank Co., Ltd.-

3 Xingquan business model prefers hybrid securities 36,092,253 6.37 Investment Fund (LOF) Industrial and Commercial Bank of China Co., Ltd.- 4 China-Europe Medical and Health Hybrid Securities Investment 24,089,364 4.25 fund China Merchants Bank Co., Ltd.-Xingquan 5 18,322,959 3.24 Herun Hybrid Securities Investment Fund Industrial Bank Co., Ltd.-Xingquan 6 New Horizons Flexible Configuration Regular Open Mixing 18,227,716 3.22 type-initiated securities investment fund Bank of China Co., Ltd.-Huabao 7 CSI Medical Trading Open Index Certificate 18,071,470 3.19 securities investment funds

8 Cao Xiaochun 12,574,874 2.22

9 Shi Xiaoli 9,566,880 1.69

Bank of Shanghai Co., Ltd.-Yinhua 10 CSI Innovative Drug Industry Trading Open 8,242,042 1.46 Index Securities Investment Fund

Announcement is hereby made.

Board of Directors of Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

June 5, 2026